stockrow
Friday 6 November 2026
Export RNLXY’s income statement to Excel — free account
Renalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024.
3.70
0.09
−2.37%
Follow RNLXY
Alert me
| Older periods | Jun '24 | Sep '24 | Dec '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
5.91 | 4.68 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(1.81) | (2.88) | — | — | |
P/B ratio |
0.00 | 0.00 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
5.43 | 6.03 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(0.42) | (0.59) | — | — | |
EV/FCF |
(0.41) | (0.58) | — | — | |
Quick Ratio |
0.52 | 0.15 | 2.22 | — | |
Current Ratio |
0.58 | 0.24 | 2.43 | — | |
Net Debt/EBITDA |
0.22 | (0.79) | 0.00 | — | |
Debt/Assets |
53.94% | 85.52% | 71.72% | 0.00% | |
Debt/Equity |
(0.55) | (0.36) | (5.99) | — | |
Asset Turnover |
0.12 | 0.19 | 0.00 | 0.00 | |
Operating CF/Net income |
1.06 | 0.81 | 0.00 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
177.89% | 176.44% | — | — | |
Selling, General and Administrative Expense of Revenue |
2,587.60% | 626.63% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(31.99%) | 48.66% | 0.00% | — | |
Graham Net Nets |
(0.66) | (1.20) | — | — | |
Graham Number |
43.60 | 45.54 | — | — | |
Earnings Yield |
(324.37%) | (329.20%) | — | — | |
Free Cash Flow Yield |
(222.12%) | (221.67%) | — | — | |
Revenue per Share |
0.28 | 0.25 | — | — | |
Operating CF per Share |
(3.47) | (1.81) | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(3.47) | (1.81) | 0.00 | — | |
Cash per Share |
2.49 | 0.43 | 0.00 | — | |
Shareholders Equity per Share |
(3.62) | (5.35) | 0.00 | — | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
(3.62) | (5.35) | 0.00 | — | |
Free Cash Flow |
(7.52) | (3.84) | (6.50) | — | |
Working Capital |
(5.00) | (9.13) | 6.59 | — | |
Capital Expenditures |
0.00 | — | — | — | |
Net Current Asset Value |
(9.03) | (13.23) | (1.62) | — | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.74 | 0.96 | 0.94 | — | |
Average Payables |
5.27 | 4.48 | 3.71 | — | |
Average Inventory |
0.20 | — | 0.42 | — | |
Average Assets |
19.30 | 12.17 | 11.36 | 4.38 | |
Average Common Equity |
(1.02) | (6.40) | (4.66) | — |
Columns are period end dates · fundamentals updated 26 Oct 2026